Cost-effectiveness of stereotactic body radiotherapy in the treatment of non–small-cell lung cancer (NSCLC): a systematic review

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Oser MG, Niederst MJ, Sequist LV, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165–e172.
   PubMed Web of Science ®Google Scholar
• Fan H, Shao Z, Xiao Y, et al. Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study. BMJ Open. 2015;5(12):e9419.
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Allen C, Barber RM, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. JAMA Oncol. 2017;3(4):524.
   PubMed Web of Science ®Google Scholar
• Ellis J. The impact of lung cancer on patients and carers. Chron Resp Dis. 2012;9(1):39–47
   PubMed Web of Science ®Google Scholar
• Migliorino MR, Santo A, Romano G, et al. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. J Cancer Res Clin. 2017;143(5):783–791.
   PubMed Web of Science ®Google Scholar
• Zarogoulidou V, Panagopoulou E, Papakosta D, et al. Estimating the direct and indirect costs of lung cancer: a prospective analysis in a Greek University Pulmonary Department. J Thorac Dis. 2015;7(Suppl 1):S12–S19.
   PubMed Web of Science ®Google Scholar
• Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:v1–v21.
   Web of Science ®Google Scholar
• Ball D, Mai GT, Vinod S, et al., Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 20(4): 494–503. 2019.
   PubMed Web of Science ®Google Scholar
• Jeppesen SS, Schytte T, Jensen HR, et al. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates. Acta Oncol. 2013;52(7):1552–1558.
   PubMed Web of Science ®Google Scholar
• Maconachie R, Mercer T, Navani N, et al. Lung cancer: diagnosis and management: summary of updated NICE guidance. BMJ. 2019;l1049. https://doi.org/10.1136/bmj.l1049
   Google Scholar
• Cao C, Wang D, Chung C, et al. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;157(1):362–373.
   PubMed Web of Science ®Google Scholar
• Senthi S, Lagerwaard FJ, Haasbeek CJ, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. 2012;13(8):802–809.
   PubMed Web of Science ®Google Scholar
• Ddema D, Aarts MJ, De Jaeger K, et al. Video-assisted thoracic lobectomy versus stereotactic body radiotherapy for stage I non- small cell lung cancer in elderly patients: a propensity matched comparative analysis. Eur Respir J. 2019;53(6):1801561.
   PubMed Web of Science ®Google Scholar
• Nyman J, Hallqvist A, Lund J, et al. SPACE-A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol. 2016;121(1):1–8.
   PubMed Web of Science ®Google Scholar
• Tandberg DJ, Tong BC, Ackerson BG, et al. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: a comprehensive review. Cancer. 2018;124(4):667–678.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sanders GD. Cost-Effectiveness Analysis 2.0. N Engl J Med. 2017;376(3):203–205.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–94.
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Sullivan SD, Neumann PJ, et al., Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 9(1): 53–61. 2003.
   PubMedGoogle Scholar
• Spiegel BM, Targownik LE, Kanwal F, et al. The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal. Gastroenterology. 2004;127(2):403–411.
   PubMed Web of Science ®Google Scholar
• Puri V, Crabtree TD, Kymes S, et al. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis. J Thorac Cardiovasc Surg. 2012;143(2):428–436.
   PubMed Web of Science ®Google Scholar
• Sher DJ, Wee JO, Punglia RS. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(5):e767–e774.
   PubMed Web of Science ®Google Scholar
• Shah A, Hahn SM, Stetson RL, et al. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. Cancer. 2013;119(17):3123–3132.
   PubMed Web of Science ®Google Scholar
• Smith BD, Jiang J, Chang JY, et al. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. J Geriatr Oncol. 2015;6(4):324–331.
   PubMed Web of Science ®Google Scholar
• Lester-Coll NH, Rutter CE, Bledsoe TJ, et al. Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. Int J Radiat Oncol Biol Phys. 2016;95(2):663–672.
   PubMed Web of Science ®Google Scholar
• Tb L Jr, Grills IS, Kestin LL, et al. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer. Am J Clin Oncol. 2011;34(5):494–498.
   PubMed Web of Science ®Google Scholar
• Mitera G, Swaminath A, Rudoler D, et al. Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non-small-cell lung cancer. J Oncol Pract. 2014;10(3):e130–6.
   PubMedGoogle Scholar
• Louie AV, Rodrigues GB, Palma DA, et al. Measuring the Population Impact of Introducing Stereotactic Ablative Radiotherapy for Stage I Non‐Small Cell Lung Cancer in Canada. Oncologist. 2014;19(8):880–885.
   PubMed Web of Science ®Google Scholar
• Grutters JP, Pijls-Johannesma M, Ruysscher DD, et al. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev. 2010;36(6):468–476.
   PubMed Web of Science ®Google Scholar
• Wolff HB, Alberts L, van der Linden N, et al. Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: a modeling study. Lung Cancer. 2020;141:89–96.
   PubMed Web of Science ®Google Scholar
• Paix A, Noel G, Falcoz PE, et al. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer. Radiother Oncol. 2018;128(3):534–540.
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322–338.
   PubMed Web of Science ®Google Scholar
• Shinde A, Li R, Kim J, et al. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. Semin Oncol. 2018;45(4):210–219.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Maciejewski ML, Basu A. Overview of Cost-effectiveness Analysis. JAMA. 2019;321(14):1400–1401.
   PubMed Web of Science ®Google Scholar
• Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5–21.
   PubMed Web of Science ®Google Scholar
• Amin NP, Sher DJ, Konski AA. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013. Appl Health Econ Health Policy. 2014;12(4):391–408.
   PubMedGoogle Scholar
• Hayes JH, Ollendorf DA, Pearson SD, et al. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med. 2013;158(12):853–860.
   PubMed Web of Science ®Google Scholar
• NICE Guideline Updates Team (UK). Evidence reviews for the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC: lung cancer: diagnosis and management: evidence review D. London: National Institute for Health and Care Excellence (UK); 2019 Mar.
   Google Scholar